Peptide 101: Tirzepatide (Mounjaro / Zepbound)
Tirzepatide (Mounjaro/Zepbound) is an FDA-approved weekly injection that activates two metabolic hormones at once, making it more powerful than earlier GLP-1 medications. In clinical trials, it produced average weight loss of around 20%, approaching what surgical weight loss programs achieve. It is approved for both type 2 diabetes and obesity and has an expanding list of FDA-approved indications. Like all powerful medications, it requires medical supervision and lifelong continuation to maintain benefits.
How it works
Tirzepatide works on two 'satiety switches' in your body at the same time. GLP-1 turns down your appetite; GIP helps your body handle fat more efficiently. Together, they create a more powerful signal to eat less and burn stored energy more effectively than flipping either switch alone.
Tirzepatide is a single synthetic peptide that acts as a co-agonist at GIP and GLP-1 receptors. GLP-1 receptor activation reduces appetite, slows gastric emptying, increases satiety, and improves insulin secretion. GIP receptor activation further amplifies insulin and glucagon regulation, promotes fat storage reduction in adipose tissue via adiponectin, and may enhance brown adipose tissue thermogenesis. The synergistic dual-incretin mechanism produces greater glycemic control and weight reduction than either mechanism alone.
What the evidence shows
Overall strength of the evidence, by our read: Strong Evidence. Some of what that rests on:
SURMOUNT-1: Tirzepatide for obesity without diabetes — phase III RCT (2022) — At 72 weeks, tirzepatide 15 mg produced mean weight loss of 22.5% from baseline versus 2.4% placebo. 91% of participants achieved ≥5% weight loss at the highest dose.
SURPASS-2: Tirzepatide versus semaglutide 1 mg in type 2 diabetes (2021) — Tirzepatide (5, 10, and 15 mg) achieved superior HbA1c reduction and significantly greater weight loss compared to semaglutide 1 mg at 40 weeks.
SURMOUNT-OSA: Tirzepatide for obstructive sleep apnea (2024) — Tirzepatide significantly reduced apnea-hypopnea index and improved sleep-related quality of life in adults with obesity and moderate-to-severe OSA, supporting FDA approval for this indication.
Preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety — the honest version
Nausea (most common, especially during dose escalation), vomiting, diarrhea, constipation, decreased appetite. Injection site reactions. Rare but serious: pancreatitis, cholelithiasis, diabetic retinopathy (in diabetics), hypoglycemia (when combined with insulin/sulfonylureas). Black box warning for thyroid C-cell tumors (based on rodent data — human relevance uncertain). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2.
Reasons to avoid it, or to talk to a clinician first:
Personal or family history of medullary thyroid carcinoma (FDA boxed warning)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (FDA boxed warning)
Known hypersensitivity to tirzepatide or any component
History of pancreatitis
Pregnancy or breastfeeding
This is not a complete safety list, and none of it is dosing advice.
Questions worth bringing to a clinician
Am I a candidate for tirzepatide for diabetes management, weight management, or both?
What is the expected trajectory of weight loss and how long should treatment continue?
What are the risks of pancreatitis, thyroid C-cell tumors, and gallbladder disease with this medication?
New research, translated
Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort
CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, o…
Transferrin participates in the pathogenesis of endometriosis by influencing the proliferation, migration and apoptosis of endometrial cells
Ferroptosis is linked to various diseases, but the role of transferrin (TF) in endometriosis (EM) remains unclear. Expression levels of ferroptosis-related proteins, including transferrin (TF), transferrin receptor (TFRC), and glutathione peroxidase 4 (GPX4), were analyzed by western blotting. Compared to normal endometrial stromal cells, eutopic and ectopic endometrial stromal cells from EM patie…
SLC33A1 exports oxidized glutathione to maintain endoplasmic reticulum redox homeostasis
The endoplasmic reticulum (ER) requires an oxidative environment to support the efficient maturation of secretory and membrane proteins. This is in part established by glutathione, a redox-active metabolite present in reduced (GSH) and oxidized (GSSG) forms. The ER maintains a higher GSSG:GSH ratio than the cytosol; however, the mechanisms controlling ER redox balance remain poorly understood. To …
What readers are asking
Topics we'll be tracking:
Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies
Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment
Cardiovascular Outcomes with Tirzepatide versus Semaglutide in Type 2 Diabetes
Peptide Disclaimer: Tirzepatide (Mounjaro, Zepbound) is an FDA-approved prescription medication indicated for: Type 2 diabetes mellitus (Mounjaro); Chronic weight management in adults with obesity or overweight (Zepbound). Any discussion of uses beyond the FDA-approved labeling is for educational purposes only and does not constitute a recommendation for off-label use. Tirzepatide is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision. Compounded versions of Tirzepatide are NOT the same as FDA-approved products. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality. The FDA has warned that compounded versions may contain different salt forms, concentrations, or impurities. Discuss the risks and regulatory status of compounded medications with your prescriber.
Medical Disclaimer: This newsletter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. No provider-patient relationship is created by reading this newsletter. Always consult your healthcare provider before making health decisions.
Peptides, medications, and supplements discussed herein may not be FDA-approved for the uses described. See substance-specific disclaimers within each article.